Research & Publications †
( † Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)
Kenneth Angermeier, MD, FACS has been a Urologist at the Cleveland Clinic Glickman Urological Institute (GUKI) since 1993. He is the director of the Cleveland Clinic Center for Genitourinary Reconstruction, a regional and national referral center for patients with disorders of the lower urinary tract and genitalia including urethral stricture, urethral fistula, urinary incontinence, Peyronie’s disease, erectile dysfunction, and congenital anomalies. He is also Professor at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.
His primary specialty interest is male lower urinary tract and genital reconstruction and prosthetic surgery, which most commonly includes urethroplasty, urethral fistula repair, implantation of genitourinary prostheses (artificial urinary sphincter, inflatable penile prosthesis, male urethral sling), correction of erectile curvature, and urinary diversion . Based on an extensive referral network, Dr. Angermeier also has significant surgical expertise in less common conditions such as genital lymphedema and penile/urethral cancer. He has lectured nationally and internationally and has authored or co-authored numerous journal articles and over 20 book chapters related to his specialty areas.
Dr. Angermeier received his Doctor of Medicine in 1985 from Indiana University with highest distinction. After completing a one-year internship in internal medicine at the Indiana University Medical Center, he served a five-year residency in urology at Cleveland Clinic. He then spent two years as a Fellow in Adult and Pediatric Reconstructive Urology at the Devine Center for Genitourinary Reconstruction and Eastern Virginia Medical School in Norfolk, Va.
In addition to full-time clinical responsibilities, Dr. Angermeier is Director of the GUKI Fellowship in Male Genitourinary Reconstruction and Prosthetic Surgery, and serves as Associate Urology Residency Program Director. Dr. Angermeier has been continually involved in clinical research throughout his career. His work has been published in various peer-reviewed journals including the Journal of Urology, Urology, BJU International, Annals of Surgery, Urologic Clinics of North America, International Journal of Impotence Research, Urologia Internationalis, Annals of Diagnostic Pathology and the International Journal of Radiation Oncology, Biology and Physics.
Dr. Angermeier has served on the Board of Directors of the Society of Genitourinary Reconstructive Surgeons in the past. He is also a past President of this organization and continues to be an active member of the Society.
Lower urinary tract reconstructive surgery, urethral stricture, urethral fistula, male urinary incontinence, erectile dysfunction, genitourinary prostheses (artificial urinary sphincter, male urethral sling, inflatable penile prosthesis), Peyronie's Disease, penile curvature, penile cancer, urethral cancer
Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.
To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists
receive or have the right to receive royalties or (iv) its physicians/scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.
As of 12/7/2015, Dr. Angermeier has reported no financial relationship with industry that is applicable to this listing. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by Cleveland Clinic. To learn more about Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.
Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers’ discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias. * Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.